tradingkey.logo
tradingkey.logo
Search

ANI Pharmaceuticals Inc

ANIP
Add to Watchlist
83.050USD
+0.270+0.33%
Close 07/01, 16:00ETQuotes delayed by 15 min
1.89BMarket Cap
20.19P/E TTM

ANI Pharmaceuticals Inc

83.050
+0.270+0.33%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+0.33%

5 Days

+0.40%

1 Month

+8.26%

6 Months

+5.21%

Year to Date

+5.21%

1 Year

+30.66%

Key Figures
83.450Open
84.820High
254.85KVolume
20.19P/E TTM
7.85P/E Dynamic
--Dividend TTM
1.11%Turnover Ratio
82.780Prev. Close
82.380Low
16.89MTurnover
LossP/E Static
3.38P/B
0.00%Div Yield TTM
6.79%ROA
99.50052wk High
0.68Volume Ratio
-20.15MNet Profit
22.89MShares
4.1138EPS TTM
0.45Beta
17.11%ROE
57.33052wk Low
2.95%Amplitude
51.78%Gross Margin
1.89BMarket Cap
5.49Reward/Risk
1.98%Risk Rate

Key Insights

ANI Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 112.33.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ANI Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
8 / 157
Overall Ranking
33 / 4564
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

ANI Pharmaceuticals Inc Highlights

StrengthsRisks
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 81.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 883.37M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 20.19, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 23.15M shares, increasing 0.25% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 49.41K shares of this stock.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
112.333
Target Price
+35.70%
Upside Space

ANI Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ANI Pharmaceuticals Inc Info

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Ticker SymbolANIP
CompanyANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
Websitehttps://www.anipharmaceuticals.com/

FAQs

What is the current price of ANI Pharmaceuticals Inc (ANIP)?

The current price of ANI Pharmaceuticals Inc (ANIP) is 83.05.

What is the symbol of ANI Pharmaceuticals Inc?

The ticker symbol of ANI Pharmaceuticals Inc is ANIP.

What is the 52-week high of ANI Pharmaceuticals Inc?

The 52-week high of ANI Pharmaceuticals Inc is 99.50.

What is the 52-week low of ANI Pharmaceuticals Inc?

The 52-week low of ANI Pharmaceuticals Inc is 57.33.

What is the market capitalization of ANI Pharmaceuticals Inc?

The market capitalization of ANI Pharmaceuticals Inc is 1.90B.

Is ANI Pharmaceuticals Inc (ANIP) currently rated as Buy, Hold, or Sell?

According to analysts, ANI Pharmaceuticals Inc (ANIP) has an overall rating of Buy, with a price target of 112.33.

What is the Earnings Per Share (EPS TTM) of ANI Pharmaceuticals Inc (ANIP)?

The Earnings Per Share (EPS TTM) of ANI Pharmaceuticals Inc (ANIP) is 3.50.